Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Company to launch product after the expiry of semaglutide patent in India
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated
